Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,193.12 -6.57 -0.21%
FTSE 100 6,686.99 5.23 0.08%
DAX 9,591.15 -8.94 -0.09%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,534.73 -195.95 -0.86%

Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody Day



Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013
Antibody Day

NEEDHAM, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc.
(Nasdaq:CLDX) announced today that Tibor Keler, Ph.D., Senior Vice President
and Chief Scientific Officer, will present an overview of the Company's
antibody technology and pipeline at the Credit Suisse Antibody Day on Friday,
May 10, 2013 at 11:00 am ET in New York.

A live webcast of the presentation will be available online on the "Events &
Presentations" page of the "Investors & Media" section of the Celldex website.
A replay of the presentation will be available for 30 days following the
event.

About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline is built from a
proprietary portfolio of antibodies and immunomodulators used alone and in
strategic combinations to create novel, disease-specific therapies that
induce, enhance or suppress the body's immune response. Visit
http://www.celldextherapeutics.com.

CONTACT: Sarah Cavanaugh
         Vice President of Investor Relations &
         Corp Communications
         Celldex Therapeutics, Inc.
         (781) 433-3161
         scavanaugh@celldextherapeutics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement